E-LIB Suche - Ergebnisse für: Callahan, Margaret K.

1

Durable complete response in a patient with leptomeningeal ..:

Lochrin, Sarah E. ; Buonocore, Darren J. ; Young, Robert J....
Pigment Cell & Melanoma Research. , 2024

Link: https://doi.org/10.1111/..

2

Integration of peripheral blood‐ and tissue‐based biomarker..:

Vanguri, Rami S ; Smithy, James W ; Li, Yanyun...
The Journal of Pathology. 261 (2023) 3 - p. 349-360 , 2023

Link: https://doi.org/10.1002/..

3

A topic modeling approach reveals the dynamic T cell compos..:

Peng, Xiyu ; Lee, Jasme ; Adamow, Matthew...
Cell Reports Methods. 3 (2023) 8 - p. 100546 , 2023

Link: https://doi.org/10.1016/..

4

Decision-Making and Health-Related Quality of Life in Patie..:

Atkinson, Thomas M ; Hay, Jennifer L ; Young Kim, Soo...
The Oncologist. 28 (2023) 4 - p. 351-357 , 2023

Link: https://doi.org/10.1093/..

5

Beyond the 5‐year milestone: Long‐term survivorship of mela..:

Loo, Kimberly ; Kalvin, Hannah L. ; Panageas, Katherine S....
Pigment Cell & Melanoma Research. 36 (2023) 3-4 - p. 314-320 , 2023

Link: https://doi.org/10.1111/..

6

Phase Ib Trial of Phenformin in Patients with V600-mutated ..:

Chapman, Paul B. ; Klang, Mark ; Postow, Michael A....
Cancer Research Communications. 3 (2023) 12 - p. 2447-2454 , 2023

Link: https://doi.org/10.1158/..

7

Tumor MHC Class I Expression Associates with Intralesional ..:

Pourmaleki, Maryam ; Jones, Caitlin J. ; Ariyan, Charlotte E....
Cancer Immunology Research. 10 (2022) 3 - p. 303-313 , 2022

Link: https://doi.org/10.1158/..

8

Safety, tolerability and efficacy of agonist anti-CD27 anti..:

Sanborn, Rachel E ; Pishvaian, Michael J ; Callahan, Margaret K...
Journal for ImmunoTherapy of Cancer. 10 (2022) 8 - p. e005147 , 2022

Link: https://doi.org/10.1136/..

9

Author Correction: Fundamental immune–oncogenicity trade-of..:

Hoyos, David ; Zappasodi, Roberta ; Schulze, Isabell...
Nature. 606 (2022) 7914 - p. E5-E5 , 2022

Link: https://doi.org/10.1038/..

10

First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist ..:

Yap, Timothy A. ; Gainor, Justin F. ; Callahan, Margaret K....
Clinical Cancer Research. 28 (2022) 17 - p. 3695-3708 , 2022

Link: https://doi.org/10.1158/..

11

Fundamental immune–oncogenicity trade-offs define driver mu..:

Hoyos, David ; Zappasodi, Roberta ; Schulze, Isabell...
Nature. 606 (2022) 7912 - p. 172-179 , 2022

Link: https://doi.org/10.1038/..

12

Inherited PD-1 deficiency underlies tuberculosis and autoim..:

Ogishi, Masato ; Yang, Rui ; Aytekin, Caner...
Nature Medicine. 27 (2021) 9 - p. 1646-1654 , 2021

Link: https://doi.org/10.1038/..

13

Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recu..:

Ready, Neal E. ; Ott, Patrick A. ; Hellmann, Matthew D....
Journal of Thoracic Oncology. 15 (2020) 3 - p. 426-435 , 2020

Link: https://doi.org/10.1016/..

14

Clinical implications of drug‐induced liver injury in early..:

Mondaca, Sebastian P. ; Liu, Dazhi ; Flynn, Jessica R....
Cancer. 126 (2020) 22 - p. 4967-4974 , 2020

Link: https://doi.org/10.1002/..

15

Defining tumor resistance to PD-1 pathway blockade: recomme..:

Kluger, Harriet M. ; Tawbi, Hussein A. ; Ascierto, Maria L....
Journal for ImmunoTherapy of Cancer. 8 (2020) 1 - p. e000398 , 2020

Link: https://doi.org/10.1136/..